Auxly Cannabis Group (XLY) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
10 Feb, 2026Executive summary
Achieved record net revenue of $38.8M in Q2 2025, up 33% year-over-year, with a 30% Adjusted EBITDA margin and eight consecutive quarters of positive Adjusted EBITDA.
Net income for Q2 2025 was $8.3M, a 315% increase year-over-year, with six-month net income of $20.4M, reversing a $24.0M loss in the prior year.
Back Forty became the #1 cannabis brand in Canada, with leadership in pre-rolls, vapes, and flower.
Strong operational foundation with coast-to-coast reach, 410 employees, and presence in 10 provinces and 2 territories.
Recognized for innovation, winning "Innovation of the Year 2024."
Financial highlights
Gross margin for Q2 2025 was 58.5%, up from 54.6% in Q2 2024; gross margin on finished cannabis inventory sold improved to 52% from 41%.
Adjusted EBITDA for Q2 2025 reached $11.6M (30% margin), a 123% increase year-over-year; net income was $8.3M, up 315%.
Cash flow from operations in Q2 2025 was $4M, up from $2.9M in Q2 2024; cash at quarter end totaled $17M.
For the six months ended June 30, 2025, net revenues were $71.5M, up 31% year-over-year.
Total assets were $258.5M at June 30, 2025, with total liabilities of $121.1M and equity of $137.4M.
Outlook and guidance
Expects continued net revenue growth in H2 2025, supported by demand, innovation, and operational efficiencies.
Rising wholesale cannabis prices and a shortage of high-quality, high-potency flower are expected to support growth and pricing power into 2025.
Global export volumes grew 48% in 2024 and are expected to increase further in 2025.
Ongoing investments in automation and efficiency are expected to drive sustainable profitability.
Plans to allocate $1.5M–$2.5M of operating cash flow to capital projects in 2025, with excess cash for balance sheet strengthening or strategic initiatives.
Latest events from Auxly Cannabis Group
- 2025 saw 24% revenue growth, 64% higher Adjusted EBITDA, and strong cash flow conversion.XLY
Q4 202526 Mar 2026 - Delivered 24% revenue growth in 2025 and leads Canadian cannabis with top brands and innovation.XLY
Investor presentation26 Mar 2026 - Q1 2025 saw 29% revenue growth, 48% gross margin, and a return to profitability, but liquidity risks persist.XLY
Q1 202511 Feb 2026 - Net loss narrowed and debt fell, but going concern risk persists amid negative working capital.XLY
Q4 202410 Feb 2026 - Q3 2024 revenue, profit, and market share rose, but liquidity and debt risks persist.XLY
Q3 202410 Feb 2026 - Record Q2 revenue and margin gains, but going concern risks persist.XLY
Q2 202410 Feb 2026 - Record Q3 2025 results and innovation position the company for growth at home and abroad.XLY
Small Cap Growth Virtual Investor Conference 202513 Dec 2025 - Q3 2025 delivered strong revenue and profit growth, with improved margins and reduced debt.XLY
Q3 202513 Nov 2025 - Record Q2 results and recapitalization position the company for profitable, efficient growth.XLY
Planet MicroCap Showcase: TORONTO 202523 Oct 2025